Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5–6 years after completion of the primary series

The tetravalent dengue vaccine (CYD-TDV; Dengvaxia®) is administered on a three-dose schedule, 6 months apart in those aged ≥9 years in a number of dengue-endemic countries in Asia and Latin America. In this study, CYD63 (NCT02824198), participants aged 9–45 years at first vaccination, and who had r...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Juliana, Archuleta, Sophia, Oh, May-Lin Helen, Shek, Lynette Pei-Chi, Jin, Jing, Bonaparte, Matthew, Fargo, Carina, Bouckenooghe, Alain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227627/
https://www.ncbi.nlm.nih.gov/pubmed/31464558
http://dx.doi.org/10.1080/21645515.2019.1661204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227627/
https://www.ncbi.nlm.nih.gov/pubmed/31464558
http://dx.doi.org/10.1080/21645515.2019.1661204

Ejemplares similares